Drug Trial Radar · NCT04559230
Sacituzumab Govitecan in Recurrent Glioblastoma
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Jan 6, 2022
Primary completion
Aug 2027
Study completion Feb 2028
Sponsor
- Lead sponsor
- The University of Texas Health Science Center at San AntonioAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein, Trophoblast cell surface antigen 2 (Trop-2), expression on treatment with Sacituzumab Govitecan (SG) versus lomustine only which has been used in the past.
Conditions
- Recurrent Glioblastoma
Interventions
Sacituzumab GovitecanDrug
Sacituzumab Govitecan will be administered by IV infusion over 3 hours for first administration and over 1 hour if tolerated. Subjects will be allowed to continue treatment until they have evidence of significant treatment-related toxicity or progressive disease.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: 6 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio · Recruiting
Texas Oncology Austin
Austin, Texas · Recruiting
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.